Determination of the optimal imaging protocol for [18F]PSMA-PET-CT for the detection of bone metastases in prostate cancer patients.

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is a widely used diagnostic tool in patients with prostate cancer (PC). However, due to the limited availability of PET scanners and relevant acquisition costs, it is important to consider the indications and acquisition time. The aim of this investigation was to determine whether a PET scan from the skull base to the proximal thigh is sufficient to detect the presence of bone metastases. A retrospective analysis was conducted on 1050 consecutive [ Of the 391 patients with bone metastases, 146 (37.3%) exhibited metastases located below the proximal thigh and 104 (26.6%) above the skull base. The majority of bone metastases located below the proximal thigh (145, 99.3%) and above the skull base (94, 90.4%) were identified in patients with more than five bone metastases. No solitary distal metastasis was detected. The PSA value correlated significantly with number of bone metastases (e. g., 1-5 vs. ≥20 bone metastases,

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Kambiz Rahbar reports honoraria from Advanced Accelerator Applications (AAA/Novartis), Bayer, Jahnsen Cielag, Amgen, Astrazeneca and Pharmtrace and a consultancy/advisory role with ABX GmbH, ABX-CRO, Bayer, and AAA/Novartis and UroTrials. Martin Boegemann receives honoraria from and has a consultancy/advisory role with Advanced Accelerator Applications (AAA/Novartis), Bayer, Janssen, Sanofi, Merck, MSD, BMS, Roche, Astellas, Exelixis, Pahrmtrace, Amgen, AstraZeneca, Eisai, Gilead, and EUSApharma.